Krishna Institute of Medical Sciences Ltd
NSE:KIMS

Watchlist Manager
Krishna Institute of Medical Sciences Ltd Logo
Krishna Institute of Medical Sciences Ltd
NSE:KIMS
Watchlist
Price: 654.95 INR -3.92% Market Closed
Market Cap: ₹262.1B

Krishna Institute of Medical Sciences Ltd
Income from Continuing Operations

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Krishna Institute of Medical Sciences Ltd
Income from Continuing Operations Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Income from Continuing Operations CAGR 3Y CAGR 5Y CAGR 10Y
Krishna Institute of Medical Sciences Ltd
NSE:KIMS
Income from Continuing Operations
₹4.1B
CAGR 3-Years
6%
CAGR 5-Years
29%
CAGR 10-Years
N/A
Apollo Hospitals Enterprise Ltd
NSE:APOLLOHOSP
Income from Continuing Operations
₹14.7B
CAGR 3-Years
10%
CAGR 5-Years
28%
CAGR 10-Years
16%
F
Fortis Healthcare Ltd
NSE:FORTIS
Income from Continuing Operations
₹9.8B
CAGR 3-Years
19%
CAGR 5-Years
N/A
CAGR 10-Years
22%
Max Healthcare Institute Ltd
NSE:MAXHEALTH
Income from Continuing Operations
₹14.2B
CAGR 3-Years
13%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Narayana Hrudayalaya Ltd
NSE:NH
Income from Continuing Operations
₹7.8B
CAGR 3-Years
16%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
G
Global Health Ltd
NSE:MEDANTA
Income from Continuing Operations
₹4.8B
CAGR 3-Years
35%
CAGR 5-Years
68%
CAGR 10-Years
N/A
No Stocks Found

Krishna Institute of Medical Sciences Ltd
Glance View

Krishna Institute of Medical Sciences Ltd. (KIMS) has steadily carved out a significant presence in the Indian healthcare sector, rooted in the ethos of delivering accessible and high-quality care. Emerging from its base in Hyderabad, the institution has expanded its reach through a network of multispecialty hospitals spread across several states in southern and western India. KIMS has built its reputation on providing a broad spectrum of healthcare services, ranging from basic preventive care to advanced super specialty treatments. By blending cutting-edge medical technology with a team of experienced professionals, it has positioned itself as a destination for both domestic and international patients seeking reliable medical solutions. The financial engine of KIMS runs on its comprehensive service offerings, which cater to a wide range of medical needs. Revenue streams are generated primarily through inpatient and outpatient services, surgical procedures, diagnostic services, and pharmacy sales. By maintaining a focus on operational efficiency and leveraging economies of scale, KIMS has managed to offer competitive pricing, thus broadening its accessibility. Furthermore, the institution has strategically enhanced its profitability through partnerships, expansions, and an emphasis on sustainability within its operations. This approach not only strengthens its market position but also fuels its capability to reinvest in infrastructure, research, and development, aiming for continuous growth and innovation in the healthcare landscape.

KIMS Intrinsic Value
442.51 INR
Overvaluation 32%
Intrinsic Value
Price ₹654.95

See Also

What is Krishna Institute of Medical Sciences Ltd's Income from Continuing Operations?
Income from Continuing Operations
4.1B INR

Based on the financial report for Mar 31, 2025, Krishna Institute of Medical Sciences Ltd's Income from Continuing Operations amounts to 4.1B INR.

What is Krishna Institute of Medical Sciences Ltd's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 5Y
29%

Over the last year, the Income from Continuing Operations growth was 23%. The average annual Income from Continuing Operations growth rates for Krishna Institute of Medical Sciences Ltd have been 6% over the past three years , 29% over the past five years .

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett